实性假乳头状胰腺肿瘤的生存结局：国家癌症数据库分析。

Survival Outcomes of Acinar Cell Pancreatic Cancer: A National Cancer Database Analysis.

机构信息

From the Department of Hematology and Oncology, Winship Cancer Institute.

Winship Research Informatics, Biostatistics, Emory University, Atlanta, GA.

出版信息

Pancreas. 2021 Apr 1;50(4):529-536. doi: 10.1097/MPA.0000000000001788.

DOI:10.1097/MPA.0000000000001788

PMID:33939665

Abstract

OBJECTIVES

Acinar cell pancreatic carcinomas (ACPCs) are rare neoplasms accounting for 1% to 2% of pancreatic tumors in adults. The objective of this study is to evaluate the benefit of chemotherapy in the adjuvant setting in resected ACPC and in the palliative setting for metastatic ACPC.

METHODS

Data were obtained from all US hospitals that contributed to the National Cancer Database between 2004 and 2014. Cases were identified using the histology code 8550.

RESULTS

A total of 593 patients with ACPC were identified. The mean age was 64.4 years (range, 18-90 years), with a male preponderance (72.8%, n = 432). Localized stage disease comprised 52.3% (n = 310) of patients. Among localized ACPC patients, 88.0% (n = 191) underwent surgery and 50.6% (n = 91) received adjuvant chemotherapy. The 5-year overall survival in those who received adjuvant treatment was slightly higher than those who did not receive adjuvant treatment (46.7% vs 44.8%, P = 0.3271). Among advanced-stage ACPC patients, 67.6% received chemotherapy, which translated into improved 5-year overall survival compared with no chemotherapy (8.1% vs 0%, P < 0.0001).

CONCLUSIONS

Chemotherapy in the palliative setting for advanced-stage ACPC patients was associated with improved survival. Adjuvant therapy did not translate into significant survival benefit.

摘要

目的

胰腺腺泡细胞癌（ACPC）是一种罕见的肿瘤，占成人胰腺肿瘤的 1%至 2%。本研究旨在评估辅助治疗中化疗对可切除 ACPC 和转移性 ACPC 姑息治疗中的益处。

方法

数据来自于 2004 年至 2014 年期间向国家癌症数据库提供数据的所有美国医院。使用组织学代码 8550 识别病例。

结果

共确定了 593 例 ACPC 患者。平均年龄为 64.4 岁（范围，18-90 岁），男性居多（72.8%，n=432）。局限性疾病占 52.3%（n=310）。在局限性 ACPC 患者中，88.0%（n=191）接受了手术，50.6%（n=91）接受了辅助化疗。接受辅助治疗的患者 5 年总生存率略高于未接受辅助治疗的患者（46.7% vs 44.8%，P=0.3271）。在晚期 ACPC 患者中，67.6%接受了化疗，与未接受化疗相比，5 年总生存率得到了改善（8.1% vs 0%，P<0.0001）。